Finding a prospective dual-target drug for the treatment of coronavirus disease by theoretical study

References

• Ahmed, S. A., Abdelrheem, D. A., El-Mageed, H. R. A., Mohamed, H. S., Rahman, A. A., Elsayed, K. N. M., & Ahmed, S. A. (2020). Destabilizing the structural integrity of COVID-19 by caulerpin and its derivatives along with some antiviral drugs: An in silico approaches for a combination therapy. Structural Chemistry, 31(6), 2391–2412. https://doi.org/10.1007/s11224-020-01586-w
   PubMed Web of Science ®Google Scholar
• Alexpandi, R., De Mesquita, J. F., Pandian, S. K., & Ravi, A. V. (2020). Quinolines-based SARS-CoV-2 CLpro and RdRp inhibitors and spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: An in silico analysis. Frontiers in Microbiology, 23(11), 1–15.
   Google Scholar
• Al-Karmalawy, A. A., Alnajjar, R., Dahab, M., Metwaly, A., & Eissa, I. (2021). Molecular docking and dynamics simulations reveal the potential of anti-HCV drugs to inhibit COVID-19 main protease. Journal of Pharmaceutical Sciences. https://doi.org/10.34172/PS.2021.3
   Google Scholar
• Amaro, R. E., Cheng, X., Ivanov, I., Xu, D., & McCammon, J. A. (2009). Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. Journal of the American Chemical Society, 131(13), 4702–4709. https://doi.org/10.1021/ja8085643
   PubMed Web of Science ®Google Scholar
• Artese, A., Svicher, V., Costa, G., Salpini, R., Di Maio, V. C., Alkhatib, M., Ambrosio, F. A., Santoro, M. M., Assaraf, Y. G., Alcaro, S., & Ceccherini-Silberstein, F. (2020). Current status of antivirals and drug gable targets of SARS CoV-2 and other human pathogenic coronaviruses. Drug Resistance Updates, 53, 100721. https://doi.org/10.1016/j.drup.2020.100721
   PubMed Web of Science ®Google Scholar
• Baildya, N., Ghosh, N. N., & Chattopadhyay, A. P. (2020). Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies. Journal of Molecular Structure, 1219, 128595. https://doi.org/10.1016/j.molstruc.2020.128595
   PubMed Web of Science ®Google Scholar
• Bauso, L. V., Imbesi, C., Irene, G., Calì, G., & Bitto, A. (2021). New approaches and repurposed antiviral drugs for the treatment of the SARS-CoV-2 infection. Pharmaceuticals, 14, 503. https://doi.org/10.3390/ph14060503
   Web of Science ®Google Scholar
• Berendsen, H. J., Postma, J. V., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath. The Journal of Chemical Physics, 81(8), 3684–3690. https://doi.org/10.1063/1.448118
   Web of Science ®Google Scholar
• Bolcato, G., Bissaro, M., Pavan, M., Sturlese, M., & Moro, S. (2020). Targeting the coronavirus SARS-CoV-2: Computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir. Scientific Reports, 10(1), 20927. https://doi.org/10.1038/s41598-020-77700-z
   PubMed Web of Science ®Google Scholar
• Boyer, C. R., Karjian, P. L., Wahl, G. M., Pegram, M., & Neuteboom, S. T. C. (2002). Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anti-Cancer Drugs, 13(1), 29–36. https://doi.org/10.1097/00001813-200201000-00003
   PubMed Web of Science ®Google Scholar
• Buonaguro, L., Tagliamonte, M., Tornesello, M. L., & Buonaguro, F. M. (2020). SARS-CoV-2 RNA polymerase as target for antiviral therapy. Journal of Translational Medicine, 18(1), 185. https://doi.org/10.1186/s12967-020-02355-3
   PubMed Web of Science ®Google Scholar
• Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., Zhou, X., Luo, H., Mao, Z., Chen, X., Xie, J., Liu, J., Cheng, H., Zhao, J., Huang, G., Wang, W., & Zhou, J. (2020). Ruxolitinib in treatment of severe coronavirus disease. (2019). (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology, 146(1), 137–146.e3. https://doi.org/10.1016/j.jaci.2020.05.019
   PubMed Web of Science ®Google Scholar
• Case, D. A., Cheatham, T. E., Darden, T., Gohlke, H., Luo, R., Merz, K. M., Onufriev, A., Simmerling, C., Wang, B., & Woods, R. J. (2005). The Amber biomolecular simulation programs. Journal of Computational Chemistry, 26(16), 1668–1688. https://doi.org/10.1002/jcc.20290
   PubMed Web of Science ®Google Scholar
• Choudhary, S., & Silakari, O. (2020). Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19. Virus Research, 289, 198146.
   PubMed Web of Science ®Google Scholar
• Copertino, D. C., Jr., Casado Lima, B. C., Duarte, R. R. R., Powell, T. R., Ormsby, C. E., Wilkin, T., Gulick, R. M., de Mulder Rougvie, M., & Nixon, D. F. (2021). Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection. Journal of Biomolecular Structure & Dynamics, 18, 1–14. https://doi.org/10.1080/07391102.2021.1901144
   Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N.log(N) method for Ewald sums in large systems. The Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Web of Science ®Google Scholar
• Dastan, F., Tabarsi Payam, P., Marjani, M., Moniri, A., Hashemian, S. M. R., Tavakoli-Ardakani, M., & Saffaei, A. (2020). Thalidomide against coronavirus disease 2019 (COVID-19): A medicine with a thousand faces. Iranian Journal of Pharmaceutical Research, 19, 1, 1–2.
   Web of Science ®Google Scholar
• Dayer, M. R., Taleb-Gassabi, S., & Dayer, M. S. (2017). Lopinavir; a potent drug against coronavirus infection: Insight from molecular docking study. Archives of Clinical Infectious Diseases, 12(4), e13823. https://doi.org/10.5812/archcid.13823
   Web of Science ®Google Scholar
• de Oliveira, M. D. L., & Oliveira, K. (2020). Comparative docking of SARS-CoV-2 receptors antagonists from repurposing drugs. https://www.researchgate.net/publication/340389889
   Google Scholar
• de Oliveira, O. V., Rocha, G. B., Paluch, A. S., & Costa, L. T. (2020). Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening. Journal of Biomolecular Structure & Dynamics, 39(11), 3924–3933. doi: 10.1080/071102.2020.1772885.
   PubMed Web of Science ®Google Scholar
• Elekhnawy, E., Kamar, A. A., & Sonbol, F. (2021). Present and future treatment strategies for coronavirus disease 2019. Future Journal of Pharmaceutical Sciences, 7(1), 84. https://doi.org/10.1186/s43094-021-00238-y.
   PubMed Web of Science ®Google Scholar
• Eweas, A. F., Alhossary, A. A., & Abdel-Moneim, A. S. (2021). Molecular docking reveals ivermectin and remdesivir as potential repurposed drugs against SARS-CoV-2. Frontiers in Microbiology, 11, 592908. https://doi.org/10.3389/fmicb.2020.592908
   PubMed Web of Science ®Google Scholar
• Fantini, J., Di Scala, C., Chahinian, H., & Yahi, N. (2020). Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. International Journal of Antimicrobial Agents, 55(5), 105960. https://doi.org/10.1016/j.ijantimicag.2020.105960
   PubMed Web of Science ®Google Scholar
• Farrokhnia, M., & Mahnam, K. (2017). Molecular dynamics and docking investigations of several zoanthamine-type marine alkaloids as matrix metaloproteinase-1 inhibitors. Iranian Journal of Pharmaceutical Research, 16(1), 173–186.
   PubMed Web of Science ®Google Scholar
• Foerch, C., Friedauer, L., Bauer, B., Wolf, T., & Adam, E. H. (2020). Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Multiple Sclerosis and Related Disorders, 42, 102180. https://doi.org/10.1016/j.msard.2020.102180
   PubMedGoogle Scholar
• Gaillard, T. (2018). Evaluation of AutoDock and AutoDock Vina on the CASF-2013 benchmark. Journal of Chemical Information and Modeling, 58(8), 1697–1706. https://doi.org/10.1021/acs.jcim.8b00312
   PubMed Web of Science ®Google Scholar
• Gaurav, D., Surojit, G., Shubham, G., Satyajit, G., Aniket, J., Ramkamal, S., Nabanita, M., Rajsekhar, R., & Surajit, G. (2020). An overview of key potential therapeutic strategies for combat in the COVID-19 battle. RSC Advances, 10, 28243.
   PubMed Web of Science ®Google Scholar
• Gohlke, H., & Case, D. A. (2004). Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf. Journal of Computational Chemistry, 25(2), 238–250. https://doi.org/10.1002/jcc.10379
   PubMed Web of Science ®Google Scholar
• Guo, Z. R. (2009). Strategy of molecular drug design: Dual-target drug design. Yao Xue Xue Bao = Acta Pharmaceutica Sinica, 44(3), 209–218. Article in Chinese.
   PubMedGoogle Scholar
• Hanson, Q. M., Wilson, K. M., Shen, M., Itkin, Z., Eastman, R. T., Shinn, P., Matthew, D., & Hall, M. D. (2020). Targeting ACE2-RBD interaction as a platform for COVID-19 therapeutics: Development and drug-repurposing screen of an AlphaLISA proximity assay. ACS Pharmacology & Translational Science, 3 (6), 1352–1360. https://doi.org/10.1021/acsptsci.0c00161
   PubMedGoogle Scholar
• Harshitha, K., & Nair, R. A. (2020). Evaluation of DNA methylation changes by CRED-RA analysis following prednisone treatment of endophyte, Fusarium oxysporum. Indian Journal of Microbiology, 60(2), 254–258. https://doi.org/10.1007/s12088-020-00857-8
   PubMed Web of Science ®Google Scholar
• Hofmann, W. P., Herrmann, E., Sarrazin, C., & Zeuzem, S. (2008). Ribavirin mode of action in chronic hepatitis C: From clinical use back to molecular mechanisms. Liver International, 28 (10), 1332–1343.
   PubMed Web of Science ®Google Scholar
• Hu, X., Zhou, Z., Li, F., Xiao, Y., Wang, Z., Xu, J., Dong, F., Zheng, H., & Yu, R. (2021). The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing. Heliyon, 7(3), e06387. https://doi.org/10.1016/j.heliyon.2021.e06387
   PubMed Web of Science ®Google Scholar
• Huynh, T., Wang, H., & Luan, B. (2020). In silico exploration of the molecular mechanism of clinically oriented drugs for possibly inhibiting SARS-CoV-2's main protease. The Journal of Physical Chemistry Letters, 11(11), 4413–4420. https://doi.org/10.1021/acs.jpclett.0c00994
   PubMed Web of Science ®Google Scholar
• Ibrahim, M. A. A., Abdelrahman, A. H. M., & Hegazy, M. E. F. (2020). In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors. Journal of Biomolecular Structure and Dynamics, 39(15), 5756–5767. https://doi.org/10.1080/07391102.2020.1791958.
   Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics, 79(2), 926–935. https://doi.org/10.1063/1.445869
   Web of Science ®Google Scholar
• Kalathiya, U., Padariya, M., Mayordomo, M., Lisowska, M., Nicholson, J., Singh, A., Baginski, M., Fahraeus, R., Carragher, N., Ball, K., Haas, J., Daniels, A., Hupp, T. R., & Alfaro, J. A. (2020). Highly conserved homotrimer cavity formed by the SARS-CoV-2 spike glycoprotein: A novel binding site. Journal of Clinical Medicine, 9(5), 1473. https://doi.org/10.3390/jcm9051473
   PubMed Web of Science ®Google Scholar
• Kim, M.-J., Kim, S. H., Park, J. A., Yu, K. L., Jang, S. I., Kim, B. S., Lee, E. S., & You, J. C. (2015). Identification and characterization of a new type of inhibitor against the human immunodeficiency virus type-1 nucleocapsid protein. Retrovirology, 12, 90. https://doi.org/10.1186/s12977-015-0218-9
   PubMed Web of Science ®Google Scholar
• Kimberly, E. (2019). Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza. P & T, 44(1), 9–11.
   PubMedGoogle Scholar
• Kiselev, O. I., Deeva, E. G., Mel'nikova, T. I., Kozeletskaia, K. N., Kiselev, A. S., Rusinov, V. L., Charushin, V. N., & Chupakhin, O. N. (2012). A new antiviral drug Triazavirin: Results of phase II clinical trial. Voprosy Virusologii, 57(6), 9–12.
   Google Scholar
• Komatsu, T. S., Okimoto, N., Koyama, Y. M., Hirano, Y., Morimoto, G., Ohno, Y., & Taiji, M. (2020). Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation. Scientific Reports, 10(1), 16986. https://doi.org/10.1038/s41598-020-74099-5
   PubMedGoogle Scholar
• Kouhpayeh, S., Shariati, L., Boshtam, M., Rahimmanesh, I., Mirian, M., Esmaeili, Y., Najaflu, M., Khanahmad, N., Zeinalian, M., Trovato, M., Tay, F. R., Khanahmad, H., & Makvandi, P. (2021). The molecular basis of COVID-19 pathogenesis, conventional and nanomedicine therapy. International Journal of Molecular Sciences, 22(11), 5438.
   PubMed Web of Science ®Google Scholar
• Kramer, M., Halleran, D., Rahman, M., Iqbal, M., Anwar, M. I., Anwar, M. I., Sabet, S., Ackad, E., Yousef, M. S., & Yousef, M. (2014). Comparative molecular dynamics simulation of hepatitis C Virus NS3/4A protease (genotypes 1b, 3a and 4b) predicts conformational instability of the catalytic triad in drug resistant strains. PLoS One, 9(8), e104425. https://doi.org/10.1371/journal.pone.0104425
   PubMed Web of Science ®Google Scholar
• Kumar, V., Kancharla, S., & Jena, M. K. (2021). In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19. Virusdisease, 32(1), 1–37. https://doi.org/10.1007/s13337-020-00643-6
   PubMedGoogle Scholar
• Leneva, I. A., Pshenichnaya, N. Y., & Bulgakova, V. A. (2020). Umifenovir and coronavirus infections: A review of research results and clinical practice. Ter Arkh, 26(92(11), 91–97. Russian.
   Google Scholar
• Lung, J., & Lin, Y. (2020). The potential SARS-CoV-2 entry inhibitor. BioRxiv. https://doi.org/10.1101/2020.03.26.009803
   Google Scholar
• Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/10.1021/acs.jctc.5b00255
   PubMed Web of Science ®Google Scholar
• Malik, S., Gupta, A., Zhong, X., Rasmussen, T. P., Manautou, J. E., & Bahal, R. (2020). Emerging therapeutic modalities against COVID-19. Pharmaceuticals, 13, 188. https://doi.org/10.3390/ph13080188
   Web of Science ®Google Scholar
• Mathur, P., Kottilil, S., & Wilson, E. (2018). Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era. Journal of Clinical and Translational Hepatology, 6(4), 431–437. https://doi.org/10.14218/JCTH.2018.00007
   PubMed Web of Science ®Google Scholar
• Meisel, E., Efros, O., Bleier, J., Beit Halevi, T., Segal, G., Rahav, G., Leibowitz, A., & Grossman, E. (2021). Folate levels in patients hospitalized with coronavirus disease 2019. Nutrients, 13(3), 812. https://doi.org/10.3390/nu13030812
   PubMed Web of Science ®Google Scholar
• Miao, M., Jing, X., De Clercq, E., & Li, G. (2020). Danoprevir for the treatment of hepatitis C virus infection: Design, development, and place in therapy. Drug Design, Development and Therapy, 14, 2759–2774. https://doi.org/10.2147/DDDT.S254754
   PubMed Web of Science ®Google Scholar
• Mittal, L., Kumari, A., Srivastava, M., Singh, M., & Asthana, S. (2021). Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. Journal of Biomolecular Structure & Dynamics, 39(10), 3662–3680. https://doi.org/10.1080/07391102.2020.1768151
   PubMed Web of Science ®Google Scholar
• Mohammad, A., Al-Mulla, F., Wei, D. Q., & Abubaker, J. (2021). Remdesivir MD simulations suggest a more favourable binding to SARS-CoV-2 RNA dependent RNA polymerase mutant P323L than wild-type. Biomolecules, 11(7), 919. https://doi.org/10.3390/biom11070919
   PubMed Web of Science ®Google Scholar
• Mohammadi, S., Heidarizadeh, M., & Entesari, M. (2020). In silico investigation on the inhibiting role of nicotine/caffeine by blocking the S protein of SARS-CoV-2 versus ACE2 receptor. Microorganisms, 8(10), 1600. https://doi.org/10.3390/microorganisms8101600
   PubMed Web of Science ®Google Scholar
• Mohammadi-Milasi, F., Mahnam, K., & Shakhsi-Niaei, M. (2020). In silico study of the association of the HLA-A*31:01 allele (human leucocyte antigen allele 31:01) with neuroantigenic epitopes of PLP (proteolipid protein), MBP (myelin basic protein) and MOG proteins (myelin oligodendrocyte glycoprotein) for studying the multiple sclerosis disease pathogenesis. Journal of Biomolecular Structure and Dynamics, 39(10), 1–25. https://doi.org/10.1080/07391102.2020.1751291.
   Google Scholar
• Mohammadpour, M., Fattahi, M. R., Sahraian, M. A., Moghadasi, A. N., & Navardi, S. (2021). Mild COVID-19 infection in a patient with multiple sclerosis, while taking fingolimod: A case report. Journal of Neurology and Neuroscience, 12, 2.
   Google Scholar
• Naydenova, K., Muir, K. W., Wu, L. F., Zhang, Z., Coscia, F., Peet, M. J., Castro-Hartmann, P., Qian, P., Sader, K., Dent, K., Kimanius, D., Sutherland, J. D., Löwe, J., Barford, D., & Russo, C. J. (2021). Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proceedings of the National Academy of Sciences of the United States of America, 118(7), e2021946118. https://doi.org/10.1073/pnas.2021946118
   PubMed Web of Science ®Google Scholar
• Nezvalova-Henriksen, K. (2021). Remdesivir, hydroxychloroquine fail to show antiviral effects in patients with COVID-19. Annals of Internal Medicine. https://doi.org/10.7326/M21-0653.
   Google Scholar
• Nukoolkarn, V., Lee, V. S., Malaisree, M., Aruksakulwong, O., & Hannongbua, S. (2008). Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. Journal of Theoretical Biology, 254(4), 861–867. https://doi.org/10.1016/j.jtbi.2008.07.030
   PubMed Web of Science ®Google Scholar
• Prajapat, M., Shekhar, N., Sarma, P., Avti, P., Singh, S., Kaur, H., Bhattacharyya, A., Kumar, S., Sharma, S., Prakash, A., & Medhi, B. (2020). Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. Journal of Molecular Graphics & Modelling, 101, 107716. https://doi.org/10.1016/j.jmgm.2020.107716
   PubMed Web of Science ®Google Scholar
• Prashantha, C. N., Gouthami, K., Lavanya, L., Bhavanam, S., Jakhar, A., Shakthiraju, R. G., Suraj, V., Sahana, K. V., Sujana, H. S., Guruprasad, N. M., & Ramachandra, R. (2021). Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. Journal of Molecular Graphics & Modelling, 102, 107769. https://doi.org/10.1016/j.jmgm.2020.107769
   PubMed Web of Science ®Google Scholar
• Rampogu, S., & Lee, K. W. (2021). Pharmacophore modelling-based drug repurposing approaches for SARS-CoV-2 therapeutics. Frontiers in Chemistry, 10, 636362.
   Google Scholar
• Rastelli, G., Rio, A. D., Degliesposti, G., & Sgobba, M. (2010). Fast and accurate predictions of binding free energies using MM/PBSA and MM/GBSA. Journal of Computational Chemistry, 31(4), 797–810.
   PubMed Web of Science ®Google Scholar
• Rice, W. G., Turpin, J. A., Huang, M., Clanton, D., Buckheit, R. W., Covell, D. G., Wallqvist, A., McDonnell, N. B., DeGuzman, R. N., Summers, M. F., Zalkow, L., Bader, J. P., Haugwitz, R. D., & Sausville, E. A. (1997). Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nature Medicine, 3(3), 341–345. https://doi.org/10.1038/nm0397-341
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham, T. E. (2013). PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. Journal of Chemical Theory and Computation, 9(7), 3084–3095. https://doi.org/10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Saeedi-Boroujeni, A., Mahmoudian-Sani, M. R., Nashibi, R., Houshmandfar, S., Tahmaseby Gandomkari, S., & Khodadadi, A. (2021). Tranilast: A potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Immunopharmacology and Immunotoxicology, 43(3), 247–258. https://doi.org/10.1080/08923973.2021.1925293
   PubMed Web of Science ®Google Scholar
• Sahoo, S. K., & Vardhan, S. (2020). Computational evidence on repurposing the anti-influenza drugs baloxavir acid and baloxavir marboxil against COVID-19. https://arxiv.org/abs/2009.01094.
   Google Scholar
• Salomon-Ferrer, R., Gotz, A. W., Poole, D., Le Grand, S., & Walker, R. C. (2013). Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald. Journal of Chemical Theory and Computation, 9(9), 3878–3888. https://doi.org/10.1021/ct400314y
   PubMed Web of Science ®Google Scholar
• Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: Current knowledge. Virology Journal, 16(1), 69.
   PubMed Web of Science ®Google Scholar
• Sheybani, Z., Dokoohaki, M. H., Negahdaripour, M., Dehdashti, M., Zolghadr, H., & Moghadami, M. (2020). The role of folic acid in the management of respiratory disease caused by COVID-19. ChemRxiv. Cambridge Open Engage.
   Google Scholar
• Singh, A., & Soliman, M. (2015). Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses. Drug Design, Development and Therapy, 9, 4137–4154.
   PubMed Web of Science ®Google Scholar
• Tariq, A., Mateen, R. M., Afzal, M. S., & Saleem, M. (2020). Paromomycin: A potential dual targeted drug effectively inhibits both spike (S1) and main protease of COVID-19. International Journal of Infectious Diseases, 98, 166–175. https://doi.org/10.1016/j.ijid.2020.06.063
   PubMed Web of Science ®Google Scholar
• Tiwari, V. (2020). Denovo design, retrosynthetic analysis and combinatorial synthesis of a hybrid antiviral (VTAR-01) to inhibit the interaction of SARS-CoV2 spike glycoprotein with human angiotensin-converting enzyme 2. Biology Open, 9, bio054056. https://doi.org/10.1242/bio.054056
   PubMed Web of Science ®Google Scholar
• Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
   PubMed Web of Science ®Google Scholar
• Unal, M. A., Bitirim, C. V., Summak, G. Y., Bereketoglu, S., Cevher Zeytin, I., Besbinar, O., Gurcan, C., Aydos, D., Goksoy, E., Kocakaya, E., Eran, Z., Murat, M., Demir, N., Aksoy Ozer, Z. B., Somers, J., Demir, E., Nazir, H., Ozkan, S. A., … Akcali, K. C. (2021). Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro. Canadian Journal of Physiology and Pharmacology, 99(5), 449–460. https://doi.org/10.1139/cjpp-2020-0734
   PubMed Web of Science ®Google Scholar
• Unni, S., Aouti, S., & Padmanabhan, B. (2020). Identification of a potent inhibitor targeting the spike protein of pandemic human coronavirus, SARS-CoV-2 by computational methods. ChemRxiv. Cambridge Open Engage.
   Google Scholar
• Uzunova, K., Filipova, E., Pavlova, V., & Vekov, T. (2020). Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 131, 110668. https://doi.org/10.1016/j.biopha.2020.110668
   PubMed Web of Science ®Google Scholar
• Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995). LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Engineering, 8(2), 127–134. https://doi.org/10.1093/protein/8.2.127
   PubMedGoogle Scholar
• Wang, E., Sun, H., Wang, J., Wang, Z., Liu, H., Zhang, J. Z. H., & Hou, T. (2019). End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chemical Reviews, 119(16), 9478–9508. https://doi.org/10.1021/acs.chemrev.9b00055
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Woods, R. J., & Chappelle, R. (2000). Restrained electrostatic potential atomic partial charges for condensed-phase simulations of carbohydrates. Theochem Journal of Molecular Structure., 527 (1-3), 149–156. https://doi.org/10.1016/S0166-1280(00)00487-5
   PubMedGoogle Scholar
• Wu, X., Yu, K., Wang, Y., Xu, W., Ma, H., Hou, Y., Li, Y., Cai, B., Zhu, L., Zhang, M., Hu, X., Gao, J., Wang, Y., Qin, H., Wang, W., Zhao, M., Wu, X., Zhang, Y., Li, L., … Yang, B. (2020). Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing, China), 6(10), 1185–1191. https://doi.org/10.1016/j.eng.2020.08.011
   PubMedGoogle Scholar
• Xia, X. (2021). Domains and functions of spike protein in SARS-Cov-2 in the context of vaccine design. Viruses, 13(1), 109. https://doi.org/10.3390/v13010109
   PubMed Web of Science ®Google Scholar
• Yoshino, R., Yasuo, N., & Sekijima, M. (2019). Molecular dynamics simulation reveals the mechanism by which the influenza cap-dependent endonuclease acquires resistance against baloxavir marboxil. Scientific Reports, 9(1), 17464. https://doi.org/10.1038/s41598-019-53945-1
   PubMedGoogle Scholar
• Yung-Fang, T., Chian-Shiu, C., Aliaksandr, A., Yarmishyn, Y. L., Yung-Hung, L., Yi-Tsung, L., Wei-Yi, L., De-Ming, Y., Shih-Jie, C., Yi-Ping, Y., Mong-Lien, W., & Shih-Hwa, C. (2020). A review of SARS-CoV-2 and the ongoing clinical trials. International Journal of Molecular Sciences, 21, 2657. https://doi.org/10.3390/ijms21072657
   PubMed Web of Science ®Google Scholar
• Zhang, X. W., & Yap, Y. L. (2004). The 3D structure analysis of SARS-CoV S1 protein reveals a link to influenza virus neuraminidase and implications for drug and antibody discovery. Theochem Journal of Molecular Structure, 681(1), 137–141. https://doi.org/10.1016/j.theochem.2004.04.065
   PubMed Web of Science ®Google Scholar